All In Biotech

Drug Trial Radar · NCT07758673

Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Apr 17, 2027

Primary completion

Jul 26, 2028

Study completion Jul 26, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety and side effects of B-cell activating factor receptor (BAFFR) chimeric antigen receptor (CAR) T cells and how well they work in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy, such as BAFFR-CAR T cells, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving BAFFR-CAR T cells may be safe, tolerable and/or effective in treating patients with relapsed or refractory B-cell ALL and B-cell lymphoblastic lymphoma.

Conditions

  • Recurrent B Acute Lymphoblastic Leukemia
  • Recurrent B Lymphoblastic Lymphoma
  • Refractory B Acute Lymphoblastic Leukemia
  • Refractory B Lymphoblastic Lymphoma

Interventions

  • Autologous BAFFR-targeting CAR T CellsBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood and CSF specimen collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration and biopsy

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • Bridge TherapyProcedure

    Receive bridging therapy

  • Chest RadiographyProcedure

    Undergo chest x-ray

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • CyclophosphamideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • FludarabineDrug

    Given IV

  • LeukapheresisProcedure

    Undergo leukapheresis

  • Magnetic Resonance ImagingProcedure

    Undergo brain MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Ultrasonographic ElastographyProcedure

    Undergo liver ultrasonographic elastography

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 28 days after chimeric antigen receptor (CAR) T cells
  2. Dose-limiting toxicityTime frame: From the start of CAR T infusion up to 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.